LEDIFOS

Ledifos is a fixed dose combination tablet containing ledipasvir 90mg and sofosbuvir 400mg. Ledipasvir is an HCV NS5A inhibitor and sofosbuvir is a nucleotide analog inhibitor of HCV NS5B polymerase.

Ledifos tablet is indicated with or without ribavirin for the treatment of patients with Chronic Hepatitis C virus (HCV) genotype 1, 4, 5 or 6 infection. The recommended dosage of Ledifos is one tablet, taken orally, once daily with or without food.